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Hepatitis C virus infects an estimated 180 million people world-
wide, prompting enormous efforts to develop inhibitors targeting
the essential NS3/4A protease. Resistance against the most promis-
ing protease inhibitors, telaprevir, boceprevir, and ITMN-191, has
emerged in clinical trials. In this study, crystal structures of the
NS3/4A protease domain reveal that viral substrates bind to the
protease active site in a conserved manner defining a consensus
volume, or substrate envelope. Mutations that confer the most
severe resistance in the clinic occur where the inhibitors protrude
from the substrate envelope, as these changes selectively weaken
inhibitor binding without compromising the binding of substrates.
These findings suggest a general model for predicting the suscept-
ibility of protease inhibitors to resistance: drugs designed to fit
within the substrate envelope will be less susceptible to resistance,
as mutations affecting inhibitor binding would simultaneously
interfere with the recognition of viral substrates.
drug design ∣ hepatitis C ∣ substrate envelope
Drug resistance is a major obstacle in the treatment of quicklyevolving diseases. Hepatitis C virus (HCV) is a genetically
diverse Hepacivirus of the Flaviviridae family infecting an esti-
mated 180 million people worldwide (1). The viral RNA genome
is translated as a single polyprotein and subsequently processed
by host-cell and viral proteases into structural (C, E1, E2, and p7)
and nonstructural (NS2, NS3, NS4A, NS4B, NS5A, and NS5B)
proteins (2). The viral RNA-dependent RNA polymerase, NS5B,
is inherently inaccurate and misincorporation of bases accounts
for a very high mutation rate (3). While some mutations are neu-
tral, others will alter the viability of the virus and propagate with
varying efficiencies in each patient. Thus HCV infected indivi-
duals will develop a heterogeneous population of virus variants
known as quasispecies (4). As patients begin treatment, the selec-
tive pressures of antiviral drugs will favor drug resistant variants
(5). Therefore, an inhibitor must not only recognize one protein
variant, but an ensemble of related enzymes. A detailed under-
standing of the atomic mechanisms of resistance is essential to
effectively combat drug resistance against HCV antivirals.
The essential HCV NS3/4A protease is an attractive therapeu-
tic target responsible for cleaving at least four sites along the viral
polyprotein. These sites share little sequence homology except
for an acid at position P6, Cys or Thr at P1, and Ser or Ala at
P1′ (Table S1). The first cleavage event at the 3-4A junction
occurs in cis as a unimolecular process, while the remaining sub-
strates are processed bimolecularly in trans. The NS3/4A protease
also cleaves the human cellular targets TRIF and MAVS, which
confounds the innate immune response to viral infection (6–8).
Early drug design efforts were hampered by the relatively shallow,
featureless architecture of the protease active site. The eventual
observation of N-terminal product inhibition served as a stepping
stone for the discovery of more potent peptidomimetic inhibitors
(9, 10). Over the past decade, pharmaceutical companies have
further developed these lead compounds. Many structure-activ-
ity-relationship (SAR) studies have been performed to evaluate
the effect of different functional moieties on protease inhibition
at positions P4-P1′ (11–17). Crystal structures have been deter-
mined of the NS3/4A protease domain bound to a variety of
inhibitors as well as of several drug resistant protease variants,
such as R155K and V36M (18, 19). These data elucidate the mo-
lecular interactions of NS3/4A with inhibitors and the effect of
specific drug resistance mutations on binding. These efforts, con-
ducted in parallel by several pharmaceutical companies, led to
the discovery of many protease inhibitors. Proof-of-concept for
the successful clinical activity of this drug class was first demon-
strated by the macrocyclic inhibitor BILN-2061 (Boehringer
Ingelheim) (20, 21), which was later dropped from clinical trials
in 2006 due to cardiotoxicity (22). Many other NS3/4A protease
inhibitors are currently in development, and telaprevir (Vertex),
boceprevir (Schering-Plough), and ITMN-191 (Intermune) lead
the way in advanced phases of human clinical trials (Fig. 1A).
Despite these successes, the rapid acquisition of drug resis-
tance has limited the efficacy of the most potent NS3/4A protease
inhibitors in both replicon studies and human clinical trials
(Fig. 1B and Table 1). In this study, we show that mutations con-
ferring the most severe resistance occur where the protease
extensively contacts the inhibitors but not the natural viral sub-
strates. Four crystal structures of the NS3/4A protease domain in
complex with the N-terminal products of viral substrates reveal a
conserved mode of substrate binding, with the consensus volume
defining the substrate envelope. The protease inhibitors ITMN-
191 (3M5L), TMC435 (3KEE) (23), and boceprevir (2OC8) (24)
protrude extensively from the substrate envelope in regions that
correlate with known sites of resistance mutations. Most notably,
the P2 moieties of all three drugs protrude to contact A156 and
R155, which mutate to confer high-level resistance against nearly
all drugs reported in the literature (25–30). These findings sug-
gest that drug resistance results from a change in molecular
recognition and imply that drugs designed to fit within the sub-
strate envelope will be less susceptible to resistance, as mutations
altering inhibitor binding will simultaneously interfere with the
binding of substrates.
Results
Synthesis of ITMN-191. We synthesized the macrocyclic inhibitor
ITMN-191 using a convergent reaction sequence described in
SI Text. Briefly, the P2 and P1-P1′ fragments were preassembled
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and the macrocyclic drug compound was generated by a four-
step reaction sequence, including P2-P3 amide coupling, ester
hydrolysis, coupling with the P1-P1′ fragment, and ring-closing
metathesis. The P2-P3 fragment was assembled by coupling the
commercially available Boc-protected amino acid (S)-2-(tert-
butoxycarbonylamino)non-8-enoic acid (Acme Biosciences, Inc)
with the preassembled P2 fragment, (3R, 5S)-5-(methoxy-
carbonyl)pyrrolidin-3-yl 4-fluoroisoindoline-2-carboxylate (31),
usingO-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexa-
fluorophosphate (HATU)/diisopropylethylamine (DIPEA). Hy-
drolysis of the P2-P3 methyl ester with LiOH:H2O in a mixture
of THF-MeOH-H2O followed by coupling of the resulting acid
under HATU/DIPEA conditions with the preassembled P1-P1′
fragment, (1R, 2S)-1-amino-N-(cyclopropylsulfonyl)-2-vinylcyclo-
propanecarboxamide (32), provided the bis-olefin precursor for
ring-closing metathesis. Cyclization of the bis-olefin intermediate
was accomplished using a highly efficient ring-closing metathesis
catalyst Zhan 1B and provided the protease inhibitor ITMN-191.
Structure Determination of Inhibitor and Substrate Complexes.
Although NS3/4A cleaves the viral polyprotein of over 3,000
residues at four specific sites in vivo, we focused on the local
interactions of the protease domain with short peptide sequences
corresponding to the immediate cleavage sites. All structural
studies were carried out with the highly soluble, single-chain con-
struct of the NS3/4A protease domain described previously (33),
which contains a fragment of the essential cofactor NS4A cova-
lently linked at the N terminus by a flexible linker. A similar pro-
tease construct was shown to retain comparable catalytic activity
to the authentic protein complex (34). Crystallization trials were
initially carried out using the inactive (S139A) protease variant
in complex with substrate peptides spanning P7-P5′. The 4A4B
substrate complex revealed cleavage of the scissile bond and no
ordered regions for the C-terminal fragment of the substrate.
Similar observations were previously described for two other
serine proteases where catalytic activity was observed, presum-
ably facilitated by water, despite Ala substitutions of the catalytic
Ser (35, 36). Thus all subsequent crystallization trials with the
NS3/4A protease were performed using N-terminal cleavage
products of the viral substrates spanning P7-P1.
NS3/4A crystal structures in complex with ITMN-191 and
peptide products 4A4B, 4B5A, and 5A5B were determined and
refined at 1.25 Å, 1.70 Å, 1.90 Å, and 1.60 Å resolution, respec-
tively (Table S2). The complexes crystallized in the space groups
P212121 and P21 with one, two, or four molecules in the asym-
metric unit. The average B factors range from 16.8–29.7 Å2
and there are no outliers in the Ramachandran plots. These
structures represent the highest resolution crystal structures of
NS3/4A protease reported to date.
Overall Structure Analysis. The NS3/4A protease domain adopts a
tertiary fold characteristic of serine proteases of the chymotrypsin
family (37, 38). A total of nine protease molecules were modeled
in the four crystal structures solved in this study with an overall
rms deviation (rmsd) of 0.28 Å. The rmsds reveal the five most
variable regions of the protease to be (Fig. S1): (i) the linker con-
necting cofactor 4A at the N terminus, (ii) the loop containing
residues 65–70, (iii) the zinc-binding site containing residues
95–105, (iv) the 310 helix region spanning residues 128–136,
and (v) the active site antiparallel β-sheet containing residues
156–168. These structural differences likely indicate inherent
flexibility in the protease and do not appear to correlate with
ligand type or active site occupancy.
Analysis of Product Complexes. Product complexes 4A4B, 4B5A,
and 5A5B were further analyzed with the C terminus of the
full-length NS3/4A structure (1CU1), which contains the N-term-
inal cleavage product of viral substrate 3-4A (39). All four
products bind to the protease active site in a conserved manner
(Fig. 2), forming an antiparallel β-sheet with residues 154–160
Fig. 1. NS3/4A protease inhibitors and reported sites of drug resistance.
(A) The leading protease inhibitors in development mimic the N-terminal side
of the viral substrates. (B) The majority of reported drug resistance mutations
cluster around the protease active site with the catalytic triad depicted in
yellow.
Table 1. Drug resistance mutations reported in replicon studies and
clinical trials*
Residue Mutation Drug
V36 A, M, L, G Boceprevir, telaprevir
Q41 R Boceprevir, ITMN-191
F43 S, C, V, I Boceprevir, telaprevir, ITMN-191,
TMC435
V55 A Boceprevir
T54 A, S Boceprevir, telaprevir
Q80 K, R, H, G, L TMC435
S138 T ITMN-191, TMC435†
R155 K, T, I, M, G, L, S, Q Boceprevir, telaprevir, ITMN-191,
BILN-2061, TMC435
A156 V, T, S, I, G Boceprevir, telaprevir, ITMN-191,
BILN-2061, TMC435
V158 I Boceprevir
D168 A, V, E, G, N, T, Y, H, I ITMN-191, BILN-2061, TMC435
V170 A Boceprevir, telaprevir
M175 L Boceprevir
*References (18, 25, 26, 28, 30–37).
†TMC435 displays reduced activity against S138T, but the mutation was not
observed in selection experiments.
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and burying 500–600 Å2 of solvent accessible surface area as cal-
culated by PISA (40). The peptide backbone torsions are very
similar, being most conserved at position P1 and deviating slightly
toward position P4. Eight hydrogen bonds between backbone
amide and carbonyl groups are completely conserved, involving
protease residues S159 (C159 in product 3-4A), A157, R155,
S139A, S138, and G137. S159 (C159 in product 3-4A), and
A157 each contribute two hydrogen bonds with the P5 and P3
peptide residues, respectively. All P1 terminal carboxyl groups
sit in the oxyanion hole, hydrogen bonding with the Nϵ atom
of H57 and the amide nitrogens of residues 137–139. Although
only product 4B5A contains a proline at P2, the other substrate
sequences still adopt constrained P2 φ torsion angles. Thus
products bind similarly despite their high sequence diversity.
The P1 and P6 residues are most conserved among the
substrate sequences, as are most of their interactions with the
protease. The P1 side chains interact with the aromatic ring of
F154. In all structures but product complex 4B5A, K165 forms
salt-bridges with the P6 acids, while residues R123, D168,
R155, and the catalytic D81 form an ionic network along one
surface of the bound products (Fig. 2). In complex 4B5A,
R123 interacts directly with the P6 acid, while D168 reorients
and no longer contacts R155. Other molecular interactions in
the product complexes are more diverse. Notably, K136 interacts
differently with the cleavage products, forming: (i) a hydrogen
bond with the P2 backbone carbonyl oxygen of 3-4A; (ii) a
salt-bridge with the P3 glutamate of product 4A4B; and (iii) non-
specific van der Waals interactions with the P2 and P3 side chains
of products 4B5A and 5A5B. Also, in product complex 4A4B, an
intramolecular hydrogen bond forms between the P3 and P5 glu-
tamate residues, while the unique P4 acid of product 3-4A forms
salt-bridges with the guanidinium groups of R123 and R155. Thus
distinct patterns of side chain interactions underlie the set of con-
served features involved in NS3/4A cleavage product binding.
The Substrate Envelope. To further analyze the structural similari-
ties of the four NS3/4A product complexes, the active sites were
superposed on the Cα atoms of residues 137–139 and 154–160,
revealing that both the active site residues and substrate products
spanning P6-P1 align closely with an average Cα rmsd of 0.24 Å
and 0.35 Å, respectively. The consensus van der Waals volume
shared by any three of the four cleavage products was then cal-
culated to generate the NS3/4A substrate envelope (Fig. 3A).
This shape could not be predicted by the primary sequences alone
and highlights the conserved mode of viral substrate recognition
despite their high sequence diversity.
Analysis of Inhibitor Complexes. ITMN-191, TMC435, and bocepre-
vir are all peptidomimetic NS3/4A protease inhibitors. Active site
superpositions of these drug complexes reveal that the inhibitors
interact with many of the same protease residues as the cleavage
products. Despite the P3-P1 cyclization of ITMN-191 and
TMC435, the functional groups are positioned similarly in all
three inhibitor complexes. The P1 cysteine surrogates interact
with the aromatic ring of F154, while the P2 and P3 moieties over-
lap closely. Although TMC435 does not contain a P4 substituent,
the P4 tert-butyl groups of ITMN-191 and boceprevir also align
closely. In addition, the P1 and P3 backbone atoms of all inhibi-
tors hydrogen bond with the carbonyl oxygens of R155 and A157,
respectively. These observations verify the peptidomimetic nat-
ure of these drugs and support their observed mechanism as
competitive active site inhibitors.
The largest variation between these three protease inhibitors
occurs at P2 where the aromatic rings of ITMN-191 and TMC435
stack against the guanidinium group of R155 (Fig. 3). This
molecular interaction alters the electrostatic network involving
R123, D168, R155, and D81. R155 rotates nearly 180° around
Cδ relative to its conformation observed in product complexes,
losing its hydrogen bond with D81 but maintaining interaction
with D168. Mutations at R155 or D168 would disrupt the elec-
trostatic network and destabilize this packing thereby lowering
the affinity of these macrocyclic drugs. This observation provides
a structural rationale for the drug resistance mutations R155K,
as previously proposed (19), and D168A/V, which both confer
a selective advantage in vitro in the presence of ITMN-191 or
TMC435 (26, 30). In addition, the TMC435 complex reveals
that R155 is stabilized by a hydrogen bond with Q80, which also
mutates to confer resistance to TMC435 (30). Thus many of the
primary drug resistance mutations can be explained by the disrup-
tion of atomic interactions involving the P2 functional groups of
the drugs.
Insights into Drug Resistance. To determine the locations where the
inhibitors protrude from the substrate envelope, the inhibitor and
product complexes were also superposed using residues 137–139
and 154–160. The van der Waals volumes of inhibitor protrusion
from the substrate envelope (V out) (41, 42) were calculated for
each drug and compared with published EC50 fold-change data
for drug resistance variants (30). The magnitudes of the EC50
fold-change data determined for each NS3/4A mutant generally
trend with the V out values for the three drugs. The P2 moieties of
boceprevir, ITMN-191 and TMC435 protrude most extensively
from the substrate envelope with V out values of 105, 294, and
Fig. 2. Stereo view of N-terminal cleavage product binding to NS3/4A pro-
tease. N-terminal protease cleavage products (A) 3-4A, (B) 4A4B, (C) 4B5A,
and (D) 5A5B are depicted as they bind to the protease active site. All
conserved interactions are indicated by black dashes, while red lines depict
interactions that are not present in all structures. The electrostatic network
involving residues R123, D168, R155, and D81 is indicated by blue dashes.
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496 Å3, respectively (Table 2). However, the precise level of drug
resistance observed is also determined by the particular change
in molecular interaction occurring for a given mutation. For ex-
ample, A156 and R155 pack with the P2 moieties of these three
inhibitors where they protrude beyond the substrate envelope.
Mutations of A156 to bulkier side chains would result in a steric
clash with the P2 drug moieties. Indeed, the rigid dimethylcyclo-
propane group of boceprevir protrudes from the substrate envel-
ope at the P2 subsite, and A156V or A156T confer 65 and 75
fold-changes in EC50, respectively (Table 2). Similarly, molecular
changes at R155 and D168 would result in a substantial loss of
interactions with P2. The most extensive protrusions of ITMN-
191 and TMC435 at P2 trend with their greatest fold-change
in potency of nearly 450 and 600, respectively, from mutations
in this subsite. Thus the extent by which an inhibitor protrudes
from the substrate envelope in a given subsite is indicative of
its vulnerability to resistance.
Further structural analyses with the substrate envelope provide
insights into other NS3/4A drug resistance mutations. The P1′
sulfonamide groups of ITMN-191 and TMC435, as well as the
P1′ ketoamide of boceprevir, protrude from the substrate envel-
ope near residues Q41 and F43, which both mutate to confer
low-level resistance to these drugs (25, 30, 43). The keto group
of boceprevir also projects outside the substrate envelope near
T54 and V55. T54A/S confers low-level resistance to boceprevir,
while V55A was recently identified in patient isolates after treat-
ment with boceprevir (44). The analogous carbonyl groups of
ITMN-191 and TMC435, however, are orientated in the opposite
direction and protrude toward S138. In fact, in vitro studies reveal
reduced activity for ITMN-191 and TMC435 against S138T
variants, while boceprevir remains fully active (30, 43). The bulky
P4 tert-butyl group of boceprevir extends outside the substrate
envelope contacting V158; the V158I variant has lower affinity
for this drug, likely due to a steric clash (45). This variant may
also impact the affinity of ITMN-191, as its P4 tert-butyl also pro-
trudes at the same location. These findings demonstrate that in
regions outside the P2 subsite, positions where ITMN-191,
TMC435, and boceprevir protrude from the substrate envelope
also correlate with many other known sites of drug resistance
mutations.
Discussion
The emergence of drug resistance is a major obstacle in modern
medicine that limits the long-term usefulness of the most promis-
ing therapeutics. By considering how HCV NS3/4A protease in-
hibitors bind relative to natural viral substrates, we discovered
that primary sites of resistance occur in regions of the protease
where drugs protrude from the substrate envelope. In particular,
R155 and A156, which mutate to confer severe resistance against
ITMN-191, TMC435, and boceprevir, interact closely with the P2
drug moieties where they protrude most extensively from the
substrate envelope. Molecular changes at these residues confer
resistance by selectively weakening inhibitor binding without
compromising the binding of viral substrates. We further specu-
late that these mutations will not considerably affect the binding
of the host cellular substrates TRIF and MAVS, which likely fit
well within the substrate envelope as they share many features
with the viral substrates. However, TRIF contains a track of
eight proline residues instead of an acidic residue at position
P6, which may modulate its binding. Further structural studies
are warranted to better ascertain the molecular details of how
these cellular substrates are recognized by the NS3/4A protease.
Although this study focuses on ITMN-191, TMC435, and
boceprevir, other NS3/4A protease inhibitors in clinical trials, in-
cluding telaprevir, narlaprevir, and vaniprevir (Fig. 1A), contain
similar functional groups that likely protrude from the substrate
envelope. Most notably, all these drug candidates contain bulky
P2 moieties and are therefore susceptible to cross-resistance
against mutations at R155 and A156. R155 and A156 mutations
have been shown to confer telaprevir resistance in treated
patients (46). Cross-resistance studies have also shown that nar-
Table 2. EC50 fold-change (FC) data * for several NS3/4A drug
resistant variants tabulated with Vout, the van derWaals volume of
protrusion from the substrate envelope, at each subsite of the
enzyme
Boceprevir ITMN-191 TMC435
Subsite
Resistance
mutation
Vout
(Å3)
EC50
FC
Vout
(Å3)
EC50
FC
Vout
(Å3)
EC50
FC
Total 292 500 649
P1 76 67 64
P2 105 294 496
Q80R 0.5 3.5 6.9
Q80K 0.8 2.3 7.7
R155K 4.7 447 30
A156V 75 63 177
A156T 65 41 44
D168A 0.7 153 594
D168E 0.8 75 40
P3 34 70 67
P4 76 69 0
V158I 3.3† ND ND
*Antiviral activity was reported previously by Lenz et al., 2010 (30).
†Fold-change in EC50 reported in replicon assay by Qiu et al., 2009 (45).
Fig. 3. Stereo view of the NS3/4A substrate envelope and protease
inhibitors. (A) After active site superpositions, the overlapping van der Waals
volume shared by any three of the four cleavage products defines the
substrate envelope, depicted in blue. NS3/4A protease residues which mutate
to confer drug resistance are shown in brown. (B) ITMN-191, (C) boceprevir
and (D) TMC435 protrude from the substrate envelope at several locations,
which correlate with known sites of drug-resistant mutations to each inhibi-
tor, shown in red.
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laprevir displays similar fold losses in activity against most of the
known drug resistance mutations for telaprevir and boceprevir
(47). Ultimately, to slow the emergence of multidrug resistant
viral strains, inhibitors should be confined within the substrate
envelope, particularly at the P2 position. To compensate for the
loss of binding affinity that will likely accompany these changes,
additional interactions could potentially be optimized spanning
the S4-S6 subsites of the protease and the catalytic triad.
Our findings further suggest a general model for using the sub-
strate envelope to predict patterns of drug resistance in other
quickly evolving diseases. For drug resistance to occur, mutations
must selectively weaken a target’s affinity for an inhibitor without
significantly altering its natural biological function. Mutations
occurring outside the substrate envelope are better able to
achieve this effect, as these molecular changes can selectively
alter inhibitor binding without compromising the binding of
natural substrates. Whenever the interaction of a drug target with
its biological substrates can be structurally characterized, we pre-
dict that drugs designed to fit within the substrate envelope will
be less susceptible to resistance. Structure-based design strategies
can utilize this model as an added constraint to develop inhibitors
that fit within the substrate envelope. In fact, previous work in
our laboratory provides proof-of-concept for the successful incor-
poration of the substrate envelope in the design of unique HIV
protease inhibitors, which maintain high affinities against a panel
of multidrug resistant variants of HIV-1 protease (42, 48–53). As
a general paradigm, design efforts incorporating the substrate
envelope would facilitate a more rationale evaluation of drug
candidates and lead to the development of more robust inhibitors
that are less susceptible to resistance.
Materials and Methods
Protein Crystallization. The NS3/4A protease construct was expressed and
purified as reported previously (33, 54), detailed in SI Text. Purified protein
was concentrated to ∼3 mg∕mL and loaded on a HiLoad Superdex75 16/60
column equilibrated with 25 mM 2-(N-morpholino)ethanesulfonic acid (MES)
at pH 6.5, 500 mM NaCl, 10% glycerol, 30 μM zinc chloride, and 2 mM DTT.
The protease fractions were pooled and concentrated to 20–25 mg∕mL with
an Amicon Ultra-15 device (10 kD; Millipore). The concentrated samples were
then incubated at 4 °C for 1 h with 2–20 M excess of viral substrate 4A4B,
peptide products 4B5A or 5A5B, or ITMN-191. Information about the synth-
esis of viral peptides and ITMN-191 is provided in SI Text. Diffraction-quality
crystals were obtained overnight for all ligands by mixing equal volume of
concentrated protein solution with precipitant solution (20–26% PEG-3350,
0.1 M sodium MES buffer at pH 6.5, and 4% ammonium sulfate) in 24-well
VDX hanging drop trays.
Data Collection and Structure Solution. Crystals were flash-frozen in liquid
nitrogen and mounted under constant cryostream. X-ray diffraction data
were collected at Advanced Photon Source BioCARS 14-IDB, 14-BMC, and
LS-CAT 21-ID-F. Diffraction intensities of the complexes were indexed,
integrated, and scaled using the programs HKL2000 (55) and XDS (56). 5%
of the data was used to calculate R-free (57). All structure solutions were
generated using isomorphous molecular replacement with PHASER (58) or
AMORE. The NS3/4A protease domain (PDB code 2A4G) (59) was used for
molecular replacement in solving the product 4A4B structure, and this struc-
ture was subsequently used for solving the other complexes. In all cases,
initial refinement was carried out in the absence of modeled ligand, which
was subsequently built in. Phases were improved using ARP/wARP (60). Itera-
tive rounds of translation, libration, and screw (TLS) and restrained refine-
ment with CCP4 (61) and graphical model building with COOT (62) until
convergence was achieved. The final structures were evaluated with
MolProbity (63) prior to deposition in the protein data bank.
Structural Analysis. Double-difference plots (64) were used to determine the
structurally invariant regions of the protease, consisting of residues 32–36,
42–47, 50–54, 84–86, and 140–143. Structures were superposed with
PyMOL (65) using the Cα atoms of these residues for all protease molecules
from the solved structures (nine total). The B chain of product complex
4A4B was used as the reference structure in all alignments. Fit of individual
inhibitors into the substrate envelope was quantified by mapping the
substrate envelope and the van der Waals volume of each inhibitor on a
three-dimensional grid with spacing of 0.5 Å. Vout for each drug moiety
was computed by counting the grid cells, which were occupied by any inhi-
bitor atom of that site but not the substrate envelope, and multiplied by
the grid cell size, 0.125 Å3 (41, 42).
Substrate Envelope and Inhibitor Analyses. NS3/4A substrate envelope was
computed using product complexes 4A4B (B chain), 4B5A (D chain), and
5A5B (A chain). In structures with multiple protease molecules in the asym-
metric unit, the one containing the most ordered peptide product was used
for the alignment. The protease domain of the full-length NS3/4A structure
(A chain; PDB code 1CU1) (39), including the C-terminal six amino acids,
was included as a product complex 3-4A. All active site alignments were
performed in PyMOL using Cα atoms of protease residues 137–139 and
154–160. After superposition, Gaussian object maps were generated in Py-
MOL for each cleavage product. Four consensus Gaussian maps were then
calculated, representing the intersecting volume of a group of three object
maps. Finally, the summation of these four consensus maps was generated to
construct the substrate envelope, depicting the van der Waals volume shared
by any three of the four products. The previously determined boceprevir
complex (PDB code 2OC8) (24) and TMC435 complex (PDB code 3KEE) (23)
were used in this study (66).
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